Neogen Timeline

2019

  • We closed more than 300 licensing agreements in over 55 countries till today.

2018

  • Submission of our first own ANDA in the US.

2017

  • The Riverside Company invests in Alter Pharma Group.

2016

  • Incorporation of Milla Pharmaceuticals Inc. in the USA.
  • First own submission in the USA.

2015

  • First marketing authorization granted in the USA.

2014

  • Extension to supply related activities by Generic Pharma International Limited, based in Ireland.

2013

  • Launch of the first oral product: Paracetamol tabs.

2012

  • Expansion to many different countries, first Paracetamol IV submission in the US.
  • Opening of  Dublin office.

2011

  • Move to Anderlecht, Brussels office.
  • Launch of Paracetamol IV in different countries.

2010

  • Creation of Alter Pharma NV to support new ventures in developments of other forms.
  •  Decentralized Procedure (DCP) approval for Paracetamol IV in 20 countries.

2009

  • Submission of Paracetamol IV, Zoledronic acid 4mg/5ml.
  • Marketing Authorization (MA) for Pantoprazole IV.

2008

First submission of Pantoprazole IV.

2007

Neogen was founded for the developments of  the following injectable products:

  • Paracetamol IV,
  • Pantoprazole IV,
  • Zoledronic acid IV,
  • Teicoplanine IV,
  • Fluconazole IV.

Comments are closed.